Taken together, these results suggest that the combination of gefitinib and BYL719 has a synergistic therapeutic effect on PI3K activation NSCLC by inhibiting phosphorylation of AKT in vivo. This evidence concerns the gene PIK3CB and non-small cell lung carcinoma.